Our CEO Fred Aslan spoke with Brian Orelli, PhD, of BiotechTV about our recent #IPO, the potential of NK cell therapy to achieve deep B cell depletion to treat autoimmune disease, and how Artiva’s platform can make these cell therapies broadly accessible to patients who need them. Watch below or check out the interview here: https://lnkd.in/gFpZ5DNX #biotech #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Checking in with Artiva Biotherapeutics' CEO Fred Aslan after the NK cell focused company's $167 million IPO. He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Full video: https://lnkd.in/gFpZ5DNX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent